Facebook Linkedin Soundcloud Twitter Vimeo Xing
Home Tags HER2-expressing solid tumors

Tag: HER2-expressing solid tumors

Trastuzumab Deruxtecan Offers an Effective Treatment Option for Patients with Difficult-to-treat...

ADC Review | Editorial Team
Trastuzumab deruxtecan (Enhertu®; Daiichi Sankyo and AstraZeneca; previously known as DS-8201a) is an effective treatment option for patients diagnosed with difficult-to-treat HER2-expressing solid tumors.

New Data for DS-8201 in Multiple HER2-Expressing Solid Tumors Warrants Further...

Peter Hofland
In clinical trials, trastuzumab deruxtecan or DS-8201, an investigational HER2-targeting antibody-drug conjugate or ADC being developed by Daiichi Sankyo, demonstrated preliminary antitumor activity in...
ADC Review, Journal of Antibody-drug Conjugates
ADC Review, Journal of Antibody-drug Conjugates (ISSN 2327-0152) is an international peer-reviewed publication designed to serve the needs of a diverse community of individuals including academia, life sciences, pharma, research, clinicians and physicians. Along with regulatory affairs, we also cover government authorities and representatives from payers to policymakers.

Latest

Peer Review

© 2013-2020 Sunvalley Communication, LLC. All Rights Reserved.

X